Evaluation of hemoglobin in pregnant women with thalassemia minor and intermedia

Role of hemoglobin and the effect of it’s correction on pregnancy outcome in minor and intermedia thalasemia patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016010825903N1

Enrollment

Registered

2016-02-18

Start date

2016-01-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: thalassaemia. Condition 2: Pregnancy. Cooley anaemia, Severe beta thalassaemia, Thalassaemia: Intermedia, major Pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: Prescription One or several packed cells (Bag of packed red blood cells) ) based on hemoglobin of body during surgery. Intervention 2: Control group 2: The second

Treatment - Drugs

Intervention group: Prescription One or several packed cells (Bag of packed red blood cells) ) based on hemoglobin of body during surgery

Control group 2: The second group as a control group does not receive anything

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: thalassemia minor and intermedia women and pregnant With hemoglobin over 8.5; Bearing a singleton baby; Patient with ages: 20-35 years old. Exclusion Criteria: Patients with metabolic diseases such as cushing syndrome, Hypothyroidism and hyperthyroidism; chronic diseases such as rheumatic disease, autoimmune and antiphospholipid syndrome.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Stillbirth. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments.;Spontaneous abortion. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments.;The amount of hemoglobin. Timepoint: Before intervention and once each month. Method of measurement: Venous sampling and sent to the laboratory.;Oligohydramnios. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;Fetal anomaly. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;Baby delivery method. Timepoint: during baby delivery. Method of measurement: Patient appointments and record baby's birth.;SGA (small for gestational age. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;VLBW (Very low birth weight). Timepoint: during baby delivery. Method of measurement: Patient appointments and record uterine contractions.;The number of pack cell required for injection. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments and record.	—

Measure

Time frame

Stillbirth. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments.;Spontaneous abortion. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments.;The amount of hemoglobin. Timepoint: Before intervention and once each month. Method of measurement: Venous sampling and sent to the laboratory.;Oligohydramnios. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;Fetal anomaly. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;Baby delivery method. Timepoint: during baby delivery. Method of measurement: Patient appointments and record baby's birth.;SGA (small for gestational age. Timepoint: Once each month, during pregnancy. Method of measurement: sonography.;VLBW (Very low birth weight). Timepoint: during baby delivery. Method of measurement: Patient appointments and record uterine contractions.;The number of pack cell required for injection. Timepoint: Once each month, during pregnancy. Method of measurement: Patient appointments and record.

—

Secondary

Measure	Time frame
Blood transfusion complication (nausea, vomiting, fever and chills). Timepoint: During the transfusion and 2 hours after blood transfusion. Method of measurement: Oral questionnaire and patient response.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahin Bahadori

Ahvaz Jundishapur University of Medical Sciences

Bahadori.md10@yahoo.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026